. Despite high complete response rates, relapses occur in a large fraction of patients; some of these are antigen-negative and others are antigen-low 1,2,4-9 . Unlike the mechanisms that result in complete and permanent antigen loss 6,8,9 , those that lead to escape of antigen-low tumours remain unclear. Here, using mouse models of leukaemia, we show that CARs provoke reversible antigen loss through trogocytosis, an active process in which the target antigen is transferred to T cells, thereby decreasing target density on tumour cells and abating T cell activity by promoting fratricide T cell killing and T cell exhaustion. These mechanisms affect both CD28-and 4-1BB-based CARs, albeit differentially, depending on antigen density. These dynamic features can be offset by cooperative killing and combinatorial targeting to augment tumour responses to immunotherapy.
. CD19 expression was reduced in progressing 19-BBζ-treated NALM6 cells, averaging 4,500 molecules per cell, down from the starting 11,000, which remain unchanged in 19-28ζ relapses and in untreated mice (Fig. 1c) . The loss of CD19 occurred early on, as it was already present by day 14 and thus occurred in the presence of abounding CAR T cells (Fig. 1b, c and Extended Data Fig. 1f ). The same patterns were found with CD19 CARs comprising single chain Fv (scFv) antibody fragments SJ25C1 16 or FMC63 [13] [14] [15] (Extended Data Fig. 2 ). Concurrent with decreased CD19 expression in tumour cells, a large fraction of CAR T cells stained positive for CD19 (Extended Data Fig. 3a) . Notably, CD19 expression in the retrieved NALM6 cells was reversible after short-term culture (Fig. 1d ). Because there was little variation in the expression of Cd19 mRNA (Extended Data Fig. 3b ), these findings indicated that a reversible, post-transcriptional loss of CD19 occurred in the presence of CAR T cells. CD19 expression did not vary when fresh NALM6 cells were segregated from CAR T cells in transwells, but promptly decreased when T cells were co-cultured (Extended Data Fig. 3c, d ). CD19 was not lost in co-cultures with untransduced T cells or T cells expressing a non-signalling CD19 CAR (Extended Data Fig. 3d ). The transfer of CD19 protein from NALM6 cells to T cells thus displayed the hallmarks of CAR-mediated trogocytosis, as further compounded by inhibition with blockers of actin polymerization 17 (Extended Data Fig. 3e ). Co-culture with CD19-knockout NALM6 cells expressing a CD19-mCherry fusion molecule resulted in the detection of both mCherry and CD19 in T cells, demonstrating whole-protein CD19 membrane extraction (Fig. 1e) . Loading of CD19-mCherry-expressing NALM6 cells with heavy amino acids and 19-28ζ cells with light amino acids and then the sorting of mCherry-positive trogocytosis-positive (trog + ) and -negative (trog − ) singlet T cells after brief co-culture unequivocally demonstrated CD19 peptides in the trog + but not the trog − fraction (Fig. 1f , Extended Data Fig. 3f ). CD81, which forms a complex with CD19, was also detected in trog + but not trog − T cells (Fig. 1f) , while concomitantly lost in the co-cultivated NALM6 cells (Extended Data Fig. 3g ). By contrast, CD22 remained unchanged in NALM6 cells and was not detected by mass spectrometry in the T cells (Fig. 1f, Extended Data Fig. 3h, i) .
CD19 trogocytosis occurred similarly after co-culture with NALM6, SUP-B15, Raji and CD19
+ SK-OV-3 cells (Extended Data Fig. 4a ) and, importantly, after the co-incubation of autologous 19-28ζ cells with primary samples from patients with ALL or chronic lymphocytic leukaemia (CLL) (Fig. 1g, Extended Data Fig. 4b ). CAR-induced trogocytosis was observed with all other tested CAR targets, including CD22, B-cell maturation antigen (BCMA) and mesothelin (Extended Data Fig. 4c -e). The same antigen escape profile was achieved after targeting CD22 in vivo (Extended Data Fig. 5 ). NALM6 cells, which express approximately 2,000 CD22 molecules per cell at baseline levels, relapsed with expression of 750 CD22 molecules per cell after treatment with 0.2 × 10 6 22-BBζ cells (Extended Data Fig. 5c ). Trogocytic target acquisition is thus a general feature of CAR T cells, probably applying to many if not all antigens.
Co-culture of sorted trog + but not trog − CAR T cells with fresh 19-28ζ cells elicited the production of IFNγ and GzmB by 19-28ζ cells (Fig. 1h) . When stably expressing CD19 at approximately equivalent levels to those detected after trogocytosis (Extended Data Fig. 6a ), both 19-28ζ and 19-BBζ cells engaged in CD19 + T cell killing, more so in the former, consistent with their greater effector function 12, 18 (Fig. 1i) . The culture of sorted trog + and trog − T cells for 6 days revealed increasing expression of PD-1, LAG-3 and TIM-3 in trog + cells, more so in 19-28ζ than 19-BBζ cells (Fig. 1j, Extended Data Fig. 6b ). In T cells stably co-expressing CAR and CD19, those that did not succumb to T cell fratricide killing tended to acquire exhaustion markers (Extended Data Fig. 6c -e). CD19 trogocytosis was associated with diminished cell-surface CAR expression, both in vitro and in vivo, and co-localized intracellular CAR and CD19 (Extended Data Fig. 7) .
The infusion of 'fresh' 19-BBζ T cells 10 days after the initial 19-BBζ treatment failed to rescue the relapse-prone mice (Fig. 2a) , suggesting that CD19 density had already decreased to a level eluding 19-BBζ threshold efficacy. 19-28ζ CAR T cells, however, did rescue these Letter reSeArCH relapses (Fig. 2a) . Differential antigen sensitivity between the two CARs was confirmed in models using stable, graded CD19 levels (Fig. 2b , Extended Data Fig. 8 ). Mice bearing NALM6 med or NALM6 low tumours (obtained after monoalleleic or biallelic disruption of the Cd19 gene, respectively) showed diminished responses to low-dose CAR therapy, with 19-28ζ cells consistently inducing longer survival than 19-BBζ counterparts (Fig. 2b) . These studies thus confirmed that a reduction of target antigen density alone can foster CAR T cell resistance. Together with the promotion of T cell exhaustion (Fig. 1j , Extended Data Fig. 6b -e) and fratricide T cell killing (Fig. 1h, i and Extended Data Fig. 6d ), CAR target extraction is thus poised to promote antigen-low tumour relapse.
Notably, 19-BBζ cells were able to control wild-type NALM6 when administered at a higher dose (Fig. 1a) . We hypothesized that higher effector:target ratios may overcome clonal sensitivity thresholds. In microwells containing one CAR T cell and one NALM6 cell (1:1 E:T; Fig. 3a) , 19-28ζ cells were more likely to lyse NALM6 cells than 19-BBζ cells (57% versus 39% over 24 h; Fig. 3b ). The time to tumour cell death after the formation of a T cell-NALM6 cell conjugate showed that 19-28ζ cells killed NALM6 cells after 261 ± 18 min (mean ± s.e.m.), whereas 19-BBζ cells did so in 569 ± 35 min (mean ± s.e.m.) (Fig. 3b) . The lesser killing ability of 19-BBζ cells did not result from poorer antigen recognition, as the frequency of non-lytic stable conjugate formation was not less but higher than measured with 19-28ζ cells, and the time spent in a non-lytic conjugate was greater (Fig. 3c) .
In microwells containing two CAR T cells and one tumour cell (2:1 E:T; Fig. 3d ), the frequency of tumour lysis increased to about 75% for both 19-28ζ and 19-BBζ cells (Fig. 3e) . Although this increase could -1  4  11  18  25  32  39  46  53  60  67  -1  4  11  18  25  32  39  46  53  60  67  10 a, Tumour burden was monitored using bioluminescence image (average radiance, photons s −1 cm −2 sr −1 ) in mice bearing NALM6 cells after treatment with CD19 CAR T cells (n = 6-7 mice per group; two independent experiments are pooled for the 0.2 × 10 6 CAR T cell dose). NT, non-treated mice. b, Left, CAR T cell counts (n = 3-7 mice per group). Middle, EOMES/T-bet ratio (n = 3-5 mice per group). Right, expression of PD-1, LAG-3 and TIM-3 in CAR T cells (n = 3-5 mice per group). D32-D70, days 32-70. c, CD19 expression in NALM6 cells from mice treated with 19-28ζ or 19-BBζ CAR T cells (day 14; n = 3-7 mice per group; days 32-70; n = 3-9 mice per group). d, CD19 expression in ex vivo cultured NALM6 cells retrieved from 19-BBζ-treated mice at day 0 (D0; time of retrieval) or day 6 (D6) (n = 9 independent samples), or NALM6 cell in vitro (n = 4 independent samples). Fig. 9a, b) . This greater-than-expected tumour killing accorded with the observed frequency of conjugates comprising two T cells bound to the same tumour cell and the shorter time to target cell death measured for the second T cell conjugate (Fig. 3f-h ). Microwell studies using the NALM6 med and NALM6 low target cells confirmed and extended these results, showing that 19-BBζ cells were more sensitive to antigen loss than 19-28ζ cells, and revealing cooperativity between 19-28ζ cells as the CD19 density decreased ( possibility of cooperative killing previously noted in chronic infection models 19 underscores the benefit of achieving higher effector:target ratios and the potential for population-based killing to transcend clonal limitations.
These considerations raised the possibility that combinatorial targeting, which has been proposed to pre-empt the immune escape of antigen-negative tumours 5, 7 , could mitigate that of antigen-low tumours. We thus investigated combinatorial possibilities using our CD19-calibrated NALM6 lines (Extended Data Fig. 8d ). Treating mice with established NALM6 cells with 0.2 × 10 6 19-ΒΒζ cells followed by a second infusion of 0.5 × 10 6 22-28ζ or 22-BBζ cells was ineffective ( Fig. 4a) , consistent with reduced expression of CD22 and poor CAR T cell expansion (Extended Data Fig. 5b, c) . A higher CAR T cell dose (1 × 10 6 ) afforded a better survival benefit, more so with 22-28ζ cells (Fig. 4a) . Dual targeting proved more effective in preventing antigen escape (0.2 × 10 6 CD19/CD22 CAR T cells, Fig. 4b ) than sequential infusions (Fig. 4a) . If CD19 were targeted with a BBζ CAR, targeting CD22 with a 28ζ CAR proved to be much more efficacious (Fig. 4b) .
Under lower CD19-antigen density conditions, the 19-28ζ and 22-ΒΒζ combination afforded the most durable responses (Fig. 4c, d ), outperforming ΒΒζ CAR pairings. At the lowest CD19 level, 19-ΒΒζ CAR therapy could no longer be rescued by co-targeting the lowdensity CD22 target, regardless of which CD22 CAR was used. Thus, combinatorial targeting can reduce escape of tumours with low baseline or post-trogocytic target expression, provided that CAR co-stimulatory features are adapted to target antigen density (Fig. 4e) .
Different antigen expression profiles-original, negative or diminished-are associated with escape from immunotherapy 4, 6, 7, 9, 14 . This study shows that tumour cells that are engaged but not killed by T cells are susceptible to trogocytic reduction of antigen density, with several possible consequences depending on antigen density, the effector:target ratio and CAR design (Extended Data Fig. 10 ). Understanding these dynamic features provides a framework for rational CAR T cell dosing and combinatorial targeting strategies, including target-adapted CAR co-stimulatory functions.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1054-1. Letter reSeArCH 1. Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423-431 (2017 . NIH/3T3 cells expressing human CD19 served as alternative antigen-presenting cells in proliferation assays. All cells were routinely tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza). Vector constructs. 19-28ζ-LNGFR or 19-BBζ-LNGFR CARs contain the SJ25C1 or FMC63 CD19-specific scFv fragment [13] [14] [15] . 19-del-LNGFR, a CAR construct that lacks co-stimulatory and ζ-chain signalling domains, contains the SJ25C1 CD19-specific scFv. CD22-28ζ-DsRed and CD22-BBζ-DsRed CARs contain the m971 CD22-specific scFv . CAR cDNAs were cloned in the SFG γ-retroviral vector. Cd19 cDNA was cloned in SFG γ-retroviral or pLM-lentiviral vector backbone under the control of the PGK-100 promoter. The CD19-mCherry fusion was generated by fusing the mCherry sequence at the C terminus of CD19 via a GS linker and cloned into the pLM-lentiviral vector backbone. The CAR-GFP fusion has been previously described 21 . All constructs were prepared using standard molecular biology techniques. Viral supernatants were prepared as previously described 21 . T cell activation and transduction. Buffy coats from healthy donors were obtained from the New York Blood Center. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation and activated as previously described 13 . Purified PBMCs were cultured in RPMI-1640 medium supplemented with 10% FBS. Forty-eight hours after activation, T cells were transduced with retroviral supernatants by centrifugation on retronectin (Takara)-coated plates. Apheresis product and blood and bone marrow samples before and after CAR T cell infusion were obtained from patients that were consented and enrolled in phase I 19-28ζ CAR T cell clinical trials approved by the MSKCC Institutional Review Board (IRB). Clinical trials are registered under identifiers NCT01044069 and NCT00466531 at the https://clinicaltrials.gov website. CAR T cells from patients have been manufactured as previously described 16, 22 . T cell expansion. A total of 3 × 10 5 irradiated NIH/3T3 cells expressing human CD19 were plated on 24-well plates and used to stimulate 1 × 10 6 CAR T cells per ml as previously described 12 . Cells were maintained in RPMI-1640 medium supplemented with 10% FBS without addition of cytokines. For in vitro assays, CAR T cells were bead-sorted four days after T cell transduction and before co-culture with NIH/3T3 cells. CAR T cells were stained with LNGFR-PE (clone C40-1457, BD antibody followed by co-incubation with anti-PE beads (Miltenyi). All in vitro assays were performed 7 days after stimulation on CD19 + NIH/3T3 cells. T cells were enumerated using an automated cell counter (Nexcelom Bioscience). 6 FFLuc-GFP NALM6 cells were administered intravenously by tail vein injection (day −4). Four days later, 1 × 10 6 , 0.4 × 10 6 or 0.2 × 10 6 CAR T cells were administered intravenously by tail vein injection (day 0). In some experiments, a second CAR T cell infusion was administered intravenously as indicated in the text. All in vivo assays were performed with bulk transduced CAR T cells except dual antigen targeting experiments. CAR T cells co-transduced with anti-CD19 CAR and anti-CD22 CAR were bead-sorted based on the expression of anti-CD19 CAR cells. Tumour burden was measured by Bioluminescence imaging used the Xenogen IVIS Imaging System (Xenogen). Living Image software (Xenogen) was used to analyse acquired bioluminescence data. Flow cytometry. All antibodies were titrated. CAR expression was measured with Alexa-Fluor-647-conjugated goat anti-mouse Fab (Jackson ImmunoResearch) or biotinylated protein L (Thermo Scientific) followed by BV510-streptavidin (BD).
The phenotype of primary cells and cell lines was determined using the following anti-human antibodies: CD19-PE, CD19-BUV395 (clone SJ25C1, BD), CD19-BV510 (clone SJ25C1, Biolegend), CD22-PE (clone S-HCL-1, BD), CD22-BV421 (clone HIB22, BD), CD81-BV605 (clone JS-81, BD), BCMA-BV421 (clone 19F2, BD), MSLN-Alexa-Fluor-700 (clone 420411, R&D Systems), CD3-BUV737 (clone UCHT, BD), LNGFR-PE, LNGFR-PE-Cy7, LNGFR-Alexa-Fluor-647 (clone C40-1457, BD), PD-1-BV711 (clone EH121, BD), LAG-3-BV650 (clone 11C3C65, Biolegend), TIM-3-BV785 (clone F38-2E2, Biolegend), T-bet-Alexa-Fluor-647 (clone 4B10, Biolegend), EOMES-PE (clone WD1928, eBioscience), CD45-BV711 (clone HI30, BD), CD5-BB515 (clone UCHT2, BD) and CD10-PE (clone HI10a, BD). Countbright beads (Invitrogen) were used to determine the absolute number of cells according to the manufacturer's protocol. 7-AAD or DAPI was used to exclude dead cells. For fixed cells, eFluor506 fixable viability dye (eBioscience) was used. Fc Receptor Binding Inhibitor Antibody Human (eBioscience) and Fc block Mouse (Miltenyi) were used to block Fc receptors. For intracellular staining, cells were fixed and permeabilized using Intracellular Fixation and Permeabilisation Buffer set (eBioscience) according to the manufacturer's protocol. Phycoerythrin Fluorescence Quantitation Kit (BD) was used according to the manufacturer's protocol to determine the number of CD19 and CD22 molecules per cell. Data were collected using BD LSR-II and BD LSR-Fortessa cytometer. Data were analysed with FlowJo Software (Treestar). Cell sorting was performed by a BD FACSAria cell sorter. Flow cytometric trogocytosis assay. A total of 1 × 10 5 CAR T cells were cocultured with target cells in 96-well plates at a 1:1 ratio. After 1, 2 or 4 h of co-culture at 37 °C, cells were washed with FACS buffer containing PBS, 0.5 mM EDTA and 0.5% BSA. After the last wash, cells were suspended in 50 µl of FACS buffer and stained with antibodies. Cells were incubated with staining antibodies for 30 min at 4 °C. Following staining, cells were washed and then analysed by flow cytometry. 7-AAD or DAPI was used to exclude dead cells. Trogocytosis was measured by the surface loss of antigen on target cells and its acquisition on CAR T cells. For trogocytosis inhibition assays, CAR T cells were pre-treated with 1 µM latrunculin A (Sigma-Aldrich) at 37 °C for 15 min before co-incubation with target cells. Cytotoxicity assays. Bulk cytotoxicity of CAR T cells was determined by standard chromium release ( Cr release was calculated using the formula ( 51 Cr release − spontaneous release)/(maximum release − spontaneous release) × 100. For luciferase-based cytotoxic assay, NALM6 cells expressing FFluc-GFP were co-cultured in 96-well plates with CAR T cells at different E:T ratios for 18 h. Target cells alone were used to determine maximal luciferase expression (relative light units; RLU max ). After 18 h of co-culture, 50 µl luciferase substrate (Bright-Glo, Promega) was added to each well. Emitted light was detected in a luminescence plate reader or Xenogen IVIS Imaging System (Xenogen), and quantified using Living Image software (Xenogen). Lysis was determined as (1 − (RLU sample )/(RLU)) × 100. Single-cell cytotoxicity assay. For single cell CTL assays in micro-wells, chamber slides containing a micro-well grid (50 × 50 × 50 µm per well; polydimethylsiloxane) were prepared and submerged in 10% FBS in RPMI-1640 medium without phenol red 23 . Bulk 1 × 10 4 CAR + T cells already loaded with tracer dye (CellTrace Violet; Invitrogen) were seeded with unlabelled NALM6 cells at a ratio of 1:1 in the presence of 1.5 µM of propidium iodide (Life Technologies) to enable visualization of cell death. Images were acquired with an AxioObserver.Z1 microscope (Carl Zeiss) using 20×/0.5 or 40×/0.6 objectives. Appropriate excitation and emission filters were chosen to image CellTrace Violet and propidium iodide staining and bright field. Fifteen positions (1 position = 36 micro-wells) for each chamber were imaged every 10 min for 24 h. Acquired images were processed using a custom macro written on ImageJ software. Each individual well was scanned for the presence of T cells. These wells were then analysed to identify wells containing a single target cell and one or two effector T cells (as indicated in the legend of Fig. 3 ) and interactions were recorded. In wells in which conjugate formation led to target death (lytic conjugates), the duration of interaction between E:T was recorded from the formation (start point, T 0 ) to the interruption of the conjugate (end point, T PI ). Abortive T cell contacts (non-lytic conjugates) lasting at least 20 min but not leading up to target cell lysis as reflected by propidium iodide positivity within the 24 h of observation. Interruption of the non-lytic conjugate can be due to either conjugate dissociation or T cell death. Contact events lasting for only 1 frame (10 min) were not included. All analyses were performed in a blinded fashion.
Expected killing frequencies in wells with two T cells (P est.2/1 ) were calculated based on the percentage of killing observed in wells with a single target cell and one T cell (P obs.1/1 ). The frequency of killing under the hypothesis of independence (that is, simply additive killing) was calculated using the following formula: P est.2 /1 = P obs.1/1 + (P obs.1/1 − (P obs.1/1 ×P obs.1/1 )). Cooperative T cell killing is inferred if P obs.2/1 > P est.2/1 .
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CD19 gene targeting. NALM6 cells were used to generate NALM6 med , NALM6 low and CD19-knockout NALM6 cells. The gRNA sequence 'CTAGTGGTGAAGGTGGAAGG' was cloned into a PBS-gRNA-MCSV2 vector. NALM6 cells were transfected by electrotransfer of Cas9 mRNA and the PBS-gRNA-CD19-MCSV2 vector using an AgilePulse MAX system (Harvard Apparatus). For electroporation, 3 × 10 6 cells were mixed with 5 µg of Cas9 mRNA and 5 µg of PBS-gRNA-MCSV2 coding for CD19-targeted gRNA into a 0.2-cm cuvette. After electroporation, cells were seeded into culture medium and incubated at 37 °C, 5% CO 2 . Knockout efficiency for CD19 was assessed by flow cytometry and deep sequencing of the knockout site. The purification of edited cells was performed by FACS sorting. The NALM6 med cell line was repeatedly sorted. NALM6 low cells were subcloned using single-cell sorting. Deep sequencing. DNA was extracted using the DNeasy Blood&Tissue kit (Qiagen) according to the manufacturer's protocol. To confirm and track editing events in the CD19 locus, the region surrounding the site of interest was amplified using the primers (forward: GAGGCTCAGAGAGGGTAAG and reverse: GTGCCCCGGAGAGTCTG). Following end repair and A-tailing, standard Illumina-compatible forked adapters (IDT) were ligated to the amplicon using the Kapa Hyper Library Preparation kit (KK8504). After library preparation, the amplicons were sequenced on a Hiseq 4000, PE125 to a depth of approximately 100,000-1,000,000 reads. Sequencing data were analysed using the Crispresso pipeline and amplicons were automatically counted after trimming using a custom R program script. Confocal microscopy. CAR T cells expressing a CAR-GFP fusion and NALM6 cells were seeded at 1:1 ratio onto poly-l-lysine-coated glass surface chamber slides. Cells were then co-cultured at 37 °C for 1 h. Cells were fixed by adding of 4% paraformaldehyde into the culture medium (final concentration 1%) and incubating for 15 min. After fixation cells were washed twice with PBS. Cells were stained using automated system Leica Bond RX Protocol F. Monoclonal mouse anti-CD19 (clone BT51E, Leica Microsystems), chicken polyclonal anti-GFP (Abcam) and rabbit polyclonal anti-CD3 (DAKO, Tyramide Alexa-Fluor-488 (Life Technologies), with Tyramide Alexa-Fluor-594 (Life Technologies), and AffiniPure Fab fragment rabbit anti-goat IgG-Alexa-Fluor-647 (Jackson Immunoreserach) were used. For nucleus staining, cells were incubated in 5 µg ml −1 DAPI/PBS solution for 5 min. Slides were mounted using Mowiol fluorescence mounting medium (Mowiol 4-88 Reagent-Calbiochem) prepared in glycerol and Tris-HCl buffer according to the manufacturer's protocol. Cells were kept in the dark at −20 °C. For imaging, confocal z-stacks were taken at optimal imaging parameters with a LSM 880 confocal microscope with Airyscan with a 63× 1.4 NA oil immersion objective (Carl Zeiss Microimaging). ImageJ software was used to generate the figures. Transcriptome analysis. Cells were sorted into TRIzol LS (Invitrogen) and then submitted to the Integrated Genomics Operation at MSKCC for RNA extraction. After ribogreen quantification and quality control on a bioAnalyser, 500 ng of total RNA underwent library preparation using the Truseq Stranded Total RNA library preparation chemistry (Illumina), with six cycles of PCR. Samples were barcoded and run on a Hiseq 2500 1T in a 50 bp/50 bp paired-end run, using the TruSeq SBS Kit v3 (Illumina). An average of 51 million paired reads were generated per sample and the percentage of mRNA bases was 58% on average. The output FASTQ data files are mapped to the target genome using the rnaStar aligner which maps reads genomically and resolves reads across splice junctions. We use the two-pass mapping method outlined in which the reads are mapped twice. The first mapping pass uses a list of known annotated junctions from Ensembl. Novel junctions found in the first pass are then added to the known junctions and a second mapping pass is performed (on the second pass the RemoveNoncanoncial flag is used). After mapping, we post-process the output SAM files using the PICARD tools to: add read groups, AddOrReplaceReadGroups, which in additional sorts the file and coverts it to the compressed BAM format. We then compute the expression count matrix from the mapped reads using HTSeq (https://htseq.readthedocs.io/en/release_0.11.1/) and one of several possible gene model databases. The raw count matrix generated by HTSeq are then processed using the R/Bioconductor package DESeq (www-huber.embl.de/users/anders/ DESeq), which is used to both normalize the full dataset and analyse differential expression between sample groups. Quantitative mass spectrometry. Cells were lysed (8 M urea in 200 mM EPPS, pH 8.4, lysis buffer containing Roche protease inhibitor cocktail), sonicated (1 min), centrifuged (8,000g for 10 min at 4 °C) then the supernatant transferred to new tubes and protein concentration determined by BCA (Pierce). Lysates were reduced with dithiothreitol (DTT; 37 °C, 1 h), alkylated with iodoacetamide (room temperature, 30 min, dark), and quenched with an additional 5 mM DTT (room temperature, 15 min, dark). In-solution Lys-C digestion (enzyme:substrate 1:100) was performed at 37 °C for 6 h, then the urea concentration diluted to 1.3 M with buffer and trypsin was added (1:100) and further incubated another 16 h at 37 °C. Enzyme activity was quenched with trifluoroacetic acid and samples were frozen at −80 °C. Based on the BCA assay, 10 µg aliquots were removed from each sample for fractionation.
To fractionate the mixture of peptides, a five-cutter method based on the StageTip technique of Rappsibler using C18 disk (3M Empore Solid Phase Extraction Disk, 2315) was used. Before loading of samples, StageTips were conditioned with 50 µl washes of acetonitrile, 50% acetonitrile in 2.5 mM ammonium bicarbonate, then 2.5 mM ammonium bicarbonate. After washing, fractions 1-5 were eluted with 30 µl of 8, 15, 22, 30 and 50% acetonitrile in 2.5 mM ammonium bicarbonate. Fractions were frozen, lyophilized to dryness, and reconstituted in 5 µl of 0.1% formic acid for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
Fractions were analysed by Microcapillary LC coupled (Waters NanoAcquity, 100-µm i.d. × 10 cm C18 column, 1.7 µm BEH130, configured with a trap column) to a Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific). Peptides were eluted at 300 nl min −1 using a 4-h acetonitrile gradient (2-50% acetonitrile in water with 0.1% formic acid). The QE Plus was operated in automatic, data-dependent MS/MS mode with one MS full scan (380-1,800 m/z) at 70,000 mass resolution and up to ten MS/MS scans at 17,500 resolution, an isolation window of 1.5 amu and normalized collision energy of 27. Automatic gain control was set to 3 × 10 6 for MS1 and 5 × 10 4 and 60 ms max IT for MS2. MS data were processed using MaxQuant version 1.5.5.30 and the Uniprot human protein sequence database (downloaded 1 August 2017). Carbamidomethylation of C was set as a fixed modification and the following variable modifications allowed: oxidation (M), N-terminal protein acetylation, deamidation (N and Q), phosphorylation (S, T, Y). Search parameters specified an MS tolerance of 8 p.p.m., an MS/MS tolerance at 40 p.p.m. and full trypsin digestion, allowing for up to two missed cleavages. Peptides were required to be at least seven amino acids in length with 1% false discovery rates calculated at peptides level. Statistics. All experimental data are presented as mean ± s.e.m. No statistical methods were used to predetermine sample size. Appropriate statistical tests were used to analyse data, as described in the figure legends. Statistical analysis was performed on GraphPad Prism 7 software. The function 'prop.test' in R (version 3.5.1) was applied to determine P values when test of proportions with continuity correction was used. Two-sample test of proportions (one-sided) were used to evaluate: H 0 : P obs2/1 ≤ P est2/1 versus H 1 : P obs2/1 > P est2/1 . We considered the experiments as a whole and did not account for any batch or donor effect given the limited sample size. Evaluating the percentage of killing within each experimental donor could lead to inconsistent conclusions across donors and more importantly an inflated type 1 error rate. We note that our approach is more conservative by not accounting for the correlation within a donor and would probably result in increased power if we accounted for it. We opted to use a less stringent type 1 error rate of 10% on the aggregate data (significance P < 0.1). We define no cooperative effect (additive effect) to be the null hypothesis, that is, H 0 : P obs2/1 ≤ P est2/1 , which assumes T cell killing events are independent in wells containing one target cells and two effector T cells. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All in vivo data can be found in the Source Data. The RNA-sequencing data are available from Gene Expression Omnibus (GEO) under accession number GSE126753. The proteomics data are available from PRIDE database under accession number PXD012833. Other data generated for this manuscript are available from the corresponding author upon reasonable request. − FACS-sorted cells after 1 h of co-culture with NALM6 cells expressing CD19-mCherry. CD19-mCherry-expressing NALM6 cells are used as a control (n = 2 donors). g, MFI of CD81 on NALM6 cell surface co-cultured with anti-CD19 CAR T cells (n = 3 donors). h, MFI of CD22 on NALM6 cell surface co-cultured with anti-CD19 CAR T cells (data are representative of three donors, n = 3 independent samples). i, MFI of CD22 on cell surface of residual NALM6 retrieved from mouse bone marrow 14 days after 19-BBζ CAR T cell treatment (0.2 × 10 6 CAR T cell dose, n = 3 mice). ns, non-significant. P values were determined by two-sided Mann-Whitney U-test (a, e and i), binomial false discovery rate-adjusted (b), or two-way ANOVA (d). Data are mean ± s.e.m. 
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Mycoplasma contamination
All cell lines were routinely tested for mycoplasma contamination and found to be negative Commonly misidentified lines (See ICLAC register) No commonly mis-identified cell lines were used except A549 cell line.
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